Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Penumbra (DE:0P8)
FRANKFURT:0P8
Holding DE:0P8?
Track your performance easily
0P8 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€97.86 - €254.00
Previous Close€231.6
Volume0.00
Average Volume (3M)100.00
Market Cap
€8.96B
Enterprise Value€8.90B
Total Cash (Recent Filing)$291.02M
Total Debt (Recent Filing)$226.69M
Price to Earnings (P/E)269.0
Beta0.56
Next Earnings
Feb 25, 2025EPS Estimate
€0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.86
Shares Outstanding38,379,199
10 Day Avg. Volume0
30 Day Avg. Volume100
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)8.04
Price to Sales (P/S)8.03
Price to Cash Flow (P/CF)41.40
P/FCF Ratio45.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.65
Enterprise Value/Gross Profit13.04
Enterprise Value/Ebitda-2.63K
Forecast
1Y Price Target
€249.71Price Target Upside7.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Penumbra News
Bulls Say, Bears Say
Bulls Say
Product Approval And LaunchThunderbolt approval could come as early as mid-25, with the potential to increase its stroke share from currently 55-65% to 70% over time.
Regulatory ApprovalsThere were significant regulatory approvals, including US FDA clearance and CE marks for key products, which are expected to contribute to future growth.
Revenue GrowthMomentum continues to track well in PEN's US VTE business on the back of +32% YoY growth in Q3.
Bears Say
Market CompetitionThere is lingering concern over the durability of growth for PEN in this segment, particularly alongside an increasingly competitive commercial landscape.
Product GrowthThrombectomy growth slowed to 14% in 3Q24 from 25% in 2Q24.
Revenue GuidanceCaution is advised regarding 2025 revenue guidance as there is a belief that current expectations might be too optimistic.
---
Options Prices
Currently, No data available
---
Ownership Overview
3.48% Insiders
41.98% Mutual Funds
― Other Institutional Investors
32.84% Public Companies and
Individual Investors
0P8 FAQ
What was Penumbra’s price range in the past 12 months?
Penumbra lowest stock price was €97.86 and its highest was €254.00 in the past 12 months.
What is Penumbra’s market cap?
Currently, no data Available
When is Penumbra’s upcoming earnings report date?
Penumbra’s upcoming earnings report date is Feb 25, 2025 which is in 66 days.
How were Penumbra’s earnings last quarter?
Penumbra released its earnings results on Oct 30, 2024. The company reported €0.809 earnings per share for the quarter, beating the consensus estimate of €0.654 by €0.155.
Is Penumbra overvalued?
According to Wall Street analysts Penumbra’s price is currently Undervalued.
Does Penumbra pay dividends?
Penumbra does not currently pay dividends.
What is Penumbra’s EPS estimate?
Penumbra’s EPS estimate is €0.85.
How many shares outstanding does Penumbra have?
Penumbra has 38,379,200 shares outstanding.
What happened to Penumbra’s price movement after its last earnings report?
Penumbra reported an EPS of €0.809 in its last earnings report, beating expectations of €0.654. Following the earnings report the stock price went up 8.226%.
Which hedge fund is a major shareholder of Penumbra?
Among the largest hedge funds holding Penumbra’s share is PRIMECAP Management Co. It holds Penumbra’s shares valued at 8M.
---
Penumbra Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€249.71 (7.82% Upside)
€249.71 (7.82% Upside)
Blogger Sentiment
Bullish
DE:0P8 Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.81%
12-Months-Change
Fundamentals
Return on Equity
3.13%
Trailing 12-Months
Asset Growth
0.73%
Trailing 12-Months
Company Description
Penumbra
Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers thrombectomy, embolization, access, neurosurgical tools, ruby coil system, lantern, penumbra occlusion device (POD) system, packing coil, and indigo systems products. Its target markets include interventional neuroradiologists, neurosurgeons, and interventional neurologists; and interventional radiologists, vascular surgeons, and interventional cardiologists. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.
---
0P8 Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected strong performance in the U.S. market, particularly in the thrombectomy business, and improving profitability metrics. However, international challenges, particularly in China and the European reimbursement landscape, tempered the overall outlook.Read More>---
0P8 Stock 12 Month Forecast
Average Price Target
€249.71
▲(7.82% Upside)
Technical Analysis
Best Analysts Covering 0P8
1 Year
1 Year Success Rate
11/15 ratings generated profit
1 Year Average Return
+15.02%
reiterated a buy rating 2 months ago
Copying David Rescott's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +15.02% per trade.
---